For overall survival, we did not find any significant association between XRCC3 Thr241Met polymorphism and survival of NSCLC patients in overall analysis (ThrMet+MetMet vs. ThrThr, OR = 1.074, 95% CI: 0.904–1.277). The gene discussed is XRCC3; the disease is non-small cell lung carcinoma.